The challenge of p53 as prognostic and predictive factor in gliomas.
The challenge of p53 as prognostic and predictive factor in gliomas.
复制标题
p53 作为神经胶质瘤预后和预测因素的挑战。
作者：
C. Nieder;S. Petersen;C. Petersen;H. Thames
近年来，越来越多的兴趣在遗传异常和生物因素，如肿瘤抑制基因p53作为可能的预测和预后因素在胶质瘤已经出现。p53的失活可导致对细胞凋亡的抗性，这是被认为解释对DNA损伤剂没有反应的机制之一。因此，p53的失活可能与更差的预后相关。考虑到最近几项研究的不一致结果，p53是否真的与治疗反应和患者预后相关仍存在争议。因此，对文献进行了系统综述，其中包括28篇出版物。用于评估p53失活的技术变化很大。总体而言，无论组织学分级如何，大约50%或更多的星形细胞瘤标本通过免疫组织化学评价为p53阳性。8项研究仅限于单一组织学组中接受过顺铂治疗的患者。在大多数情况下，非限制性入选标准和统计方法的使用不足以纠正可能的偏倚，因此难以得出明确的结论。然而，似乎p53的预后信息是最好的边缘，特别是当与已建立的参数，如分级，年龄等，其预测价值，这是最有可能的是相当有限的，很难判断没有前瞻性研究也评价其他生物学因素，以及其他放射学进展的时间以外的终点。
In recent years, increasing interest in genetic abnormalities and biologic factors such as the tumour suppressor gene p53 as possible predictive and prognostic factor in gliomas has emerged. Inactivation of p53 can result in resistance to apoptosis, one of the mechanisms thought to explain the failure to respond to DNA-damaging agents. Thus, inactivation of p53 might be associated with a worse prognosis. Considering the inconsistent results of several recent studies, it has remained controversial whether p53 actually can be related to response to treatment and patients' prognosis. Therefore, a systematic review of the literature was performed, which included 28 publications. Techniques for assessing the inactivation of p53 varied widely. Overall, approximately 50% or more of astrocytoma specimens evaluated by immunohistochemistry stained positively for p53, regardless of histologic grade. Eight studies were restricted to comparably treated patients within a single histologic group. In most instances, non-restrictive inclusion criteria and use of statistical methods, which were not sufficient to correct the possible bias, make it difficult to reach unequivocal conclusions. However, it appears that the prognostic information of p53 is at best marginal, especially when compared to established parameters such as grading, age, etc. Its predictive value, which most likely is rather limited too, can hardly be judged without prospective studies also evaluating other biological factors as well as end-points other than time to radiological progression.
登录
查看更多内容
p53 功能影响分割放射治疗对胶质母细胞瘤的效果。
DOI：
10.1016/s0360-3016(98)00393-9
发表时间：
1999
期刊：
International journal of radiation oncology, biology, physics
影响因子：
--
作者：
Haas-Kogan,DA;Kogan,SS;Yount,G;Hsu,J;Haas,M;Deen,DF;Israel,MA
通讯作者：
Israel,MA
恶性神经胶质瘤中的肿瘤抑制基因改变：组织病理学关联和预后评估。
影响因子：
5.2
作者：
James,CD;Galanis,E;Frederick,L;Kimmel,DW;Cunningham,JM;Atherton-Skaff,PJ;O'Fallon,JR;Jenkins,RB;Buckner,JC;Hunter,SB;Olson,JJ;Scheithauer,BW
通讯作者：
Scheithauer,BW
p53 免疫反应性对神经胶质瘤患者的预后意义。
DOI：
--
发表时间：
1995
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
Kyritsis,AP;Bondy,ML;Hess,KR;Cunningham,JE;Zhu,D;Amos,CJ;Yung,WK;Levin,VA;Bruner,JM
通讯作者：
Bruner,JM
DOI：
10.1073/pnas.95.24.14453
发表时间：
1998-11-24
影响因子：
11.1
作者：
Shu, HKG;Kim, MM;Israel, MA
通讯作者：
Israel, MA
TP53突变和p53过表达与儿童恶性胶质瘤预后的关系。
DOI：
--
发表时间：
1997
期刊：
Cancer research.
影响因子：
--
作者：
Pollack,IF;Hamilton,RL;Finkelstein,SD;Campbell,JW;Martinez,AJ;Sherwin,RN;Bozik,ME;Gollin,SM
通讯作者：
Gollin,SM